PMID- 21128238
OWN - NLM
STAT- MEDLINE
DCOM- 20110921
LR  - 20160303
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 129
IP  - 6
DP  - 2011 Sep 15
TI  - Human leukocyte antigen-G expression is associated with a poor prognosis in 
      patients with esophageal squamous cell carcinoma.
PG  - 1382-90
LID - 10.1002/ijc.25807 [doi]
AB  - Human leukocyte antigen (HLA)-G inhibits functions of immune component cells and 
      promotes malignant cells evading from antitumor immunity. We investigated the 
      clinical relevance of HLA-G expression in esophageal squamous cell carcinoma 
      (ESCC). In our study, HLA-G expression in 79 primary ESCC lesions and 
      corresponding adjacent normal tissues were analyzed with immunohistochemistry. 
      Soluble HLA-G (sHLA-G) in plasma was detected with enzyme-linked immunosorbent 
      assay (ELISA) in 41 ESCC patients (including 19 case-matched lesions and plasma 
      samples) and in 153 normal healthy controls. HLA-G expression was observed in 
      65.8% (52/79) of the ESCC lesions but not in adjacent normal esophageal tissues. 
      HLA-G expression was more frequently observed in patients with advanced disease 
      stage (III/IV vs. I/II, p = 0.01). Patients with HLA-G expression had a 
      significantly worse survival, and HLA-G could be an independent prognostic 
      factor. sHLA-G levels in plasma were significantly increased in patients compared 
      to normal controls (median: 152.4 U/ml vs. 8.9 U/ml, p < 0.001). The area under 
      receiver-operating characteristic (ROC) curve for sHLA-G in plasma was 0.992. 
      However, no significant correlation was found between sHLA-G in plasma and 
      clinical parameters studied. In conclusion, our findings indicated that HLA-G 
      expression in ESCC is associated with poor survival and could be a prognostic 
      indicator. Furthermore, increased levels of sHLA-G in plasma might be a useful 
      preoperative biomarker for diagnosis.
CI  - Copyright (c) 2010 UICC.
FAU - Lin, Aifen
AU  - Lin A
AD  - Human Tissue Bank, Taizhou Hospital of Zhejiang Province, Wenzhou Medical 
      College, Zhejiang, China.
FAU - Zhang, Xia
AU  - Zhang X
FAU - Zhou, Wen-Jun
AU  - Zhou WJ
FAU - Ruan, Yan-Yun
AU  - Ruan YY
FAU - Xu, Dan-Ping
AU  - Xu DP
FAU - Wang, Qing
AU  - Wang Q
FAU - Yan, Wei-Hua
AU  - Yan WH
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110226
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (HLA Antigens)
RN  - 0 (HLA-G Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Carcinoma, Squamous Cell/blood/*immunology/mortality
MH  - Esophageal Neoplasms/blood/*immunology/mortality
MH  - Female
MH  - HLA Antigens/*metabolism
MH  - HLA-G Antigens
MH  - Histocompatibility Antigens Class I/*metabolism
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
EDAT- 2010/12/04 06:00
MHDA- 2011/09/22 06:00
CRDT- 2010/12/04 06:00
PHST- 2010/09/08 00:00 [received]
PHST- 2010/11/05 00:00 [accepted]
PHST- 2010/12/04 06:00 [entrez]
PHST- 2010/12/04 06:00 [pubmed]
PHST- 2011/09/22 06:00 [medline]
AID - 10.1002/ijc.25807 [doi]
PST - ppublish
SO  - Int J Cancer. 2011 Sep 15;129(6):1382-90. doi: 10.1002/ijc.25807. Epub 2011 Feb 
      26.